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ABSTRACT Obstructive sleep apnoea (OSA) is associated with cardiovascular disease. Dyslipidaemia has
been implicated as a mechanism linking OSA with atherosclerosis, but no consistent associations with lipids
exist for OSA or positive airway pressure treatment. We assessed the relationships between fasting lipid
levels and obesity and OSA severity, and explored the impact of positive airway pressure treatment on
2-year fasting lipid level changes.
Analyses included moderate-to-severe OSA patients from the Icelandic Sleep Apnoea Cohort. Fasting
morning lipids were analysed in 613 untreated participants not on lipid-lowering medications at baseline.
Patients were then initiated on positive airway pressure and followed for 2 years. Sub-classification using
propensity score quintiles, which aimed to replicate covariate balance associated with randomised trials and,
therefore, minimise selection bias and allow causal inference, was used to design the treatment group
comparisons. 199 positive airway pressure adherent patients and 118 non-users were identified.
At baseline, obesity was positively correlated with triglycerides and negatively correlated with total
cholesterol, and low-density and high-density lipoprotein cholesterol. A small correlation was observed
between the apnoea/hypopnoea index and high-density lipoprotein cholesterol. No effect of positive airway
pressure adherence on 2-year fasting lipid changes was observed.
Results do not support the concept of changes in fasting lipids as a primary mechanism for the increased
risk of atherosclerotic cardiovascular disease in OSA.
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Introduction
Obstructive sleep apnoea (OSA) is independently associated with atherosclerotic disease [1], but the
mechanisms remain unclear. Dyslipidaemia is central to atherosclerosis, with a strong association between
lipid levels and risk of atherosclerotic cardiovascular disease [2]. Consequently, dyslipidaemia has been
implicated as a possible mechanism linking OSA with atherosclerosis. However, studies to date have not
definitively established a relationship between the lipid profile and either OSA or positive airway pressure
treatment [3–16].
OSA is characterised by repetitive collapse of the upper airway causing chronic intermittent hypoxia. Animal
models demonstrate dyslipidaemia proportional to chronic intermittent hypoxia severity and development of
atherosclerotic lesions [9–11, 17–21]. However, while studies in mice support a causal relationship between
chronic intermittent hypoxia and dyslipidaemia, human studies evaluating the effects of OSA [3–11] and
positive airway pressure treatment [8–16] on lipid levels are inconsistent. Moreover, studies examining
positive airway pressure are of limited duration, following patients for at most 6 months [8–16].
When examining inconsistencies in the effect of positive airway pressure, one important consideration is the
impact of selection bias within observational studies. Propensity score methodologies are well-established
techniques used in numerous fields, including cardiovascular research [22], to minimise bias and perform
comparative effectiveness research in observational studies. A recent National Heart, Lung, and Blood
Institute working group highlighted the importance of such methods within observational samples [23],
which are more inclusive of real-world patients than typical randomised trials. As previously discussed
[24, 25], sub-classification using a propensity score is performed without regard to outcome data, allowing
the ‘‘design’’ of nonrandomised comparisons to examine treatment effects. In observational studies,
propensity scores are analogous to randomisation, eliminating systematic biases in nonrandomised group
comparisons due to imbalance from measured covariates, thus improving causal inference [25]. Therefore,
propensity score methods allow treatment effect analyses to proceed as if patients were randomised [24, 25].
Using the Icelandic Sleep Apnoea Cohort [26, 27], sub-classification by propensity score quintiles was
employed to compare fasting lipid level changes between positive airway pressure adherent patients and
non-users, 2 years after OSA diagnosis and treatment initiation. We also explored associations for obesity
and OSA severity with the fasting lipid profile. We hypothesised that there would be a relationship between
OSA severity and fasting lipids at baseline, and that positive airway pressure would improve fasting lipids in
adherent subjects compared to non-users in the propensity score designed comparison.
Methods
Study subjects
Patients were diagnosed with moderate-to-severe OSA (apnoea-hypopnoea index (AHI) o15 events?h-1)
and referred for positive airway pressure treatment. Participants completed standardised questionnaires,
physical examination, a type III sleep study, fasting morning blood samples and abdominal MRI (magnetic
resonance imaging) at baseline. 2 years after positive airway pressure treatment initiation, participants were
invited for a follow-up visit where they answered the same questionnaires, underwent physical examination
and anthropometric measures and fasting morning blood samples were taken, as in baseline assessment.
Analyses were restricted to patients not using lipid-lowering medications. Details of the analysis sample
obtained from the Icelandic Sleep Apnoea Cohort are presented in figure E1 and have been published
previously [26, 27]. Written consent was obtained from every participant. The study protocol was approved
by the National Bioethics Committee, the Data Protection Authority of Iceland and the University of
Pennsylvania Institutional Review Board (Philadelphia, PA, USA).
Blood samples
Fasting blood samples were taken the morning after sleep in untreated participants at baseline and follow-
up (online supplementary material). Total cholesterol, high-density lipoprotein cholesterol (HDL-C) and
triglyceride concentrations were measured. Low-density lipoprotein cholesterol (LDL-C) was calculated
using the Friedwald equation (LDL-C 5 total cholesterol – HDL-C – triglyceride/5). Indicators of
‘‘abnormal’’ levels were defined using the National Cholesterol Education Program (NCEP) Adult
Treatment Panel III (ATPIII) criteria [28]: total cholesterol o200 mg?dL-1, LDL-C o130 mg?dL-1,
triglycerides o150 mg?dL-1 and HDL-C ,40 mg?dL-1.
Positive airway pressure adherence
Patients were followed for 2 years after positive airway pressure treatment initiation. Positive airway
pressure adherence was based on objective usage data from memory cards over the last 28 days, if available,
or else on subjective questionnaires (validation of subjective criteria presented in online supplementary
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material). Adherent patients used positive airway pressure for o4 h per night and for o20 of the last
28 nights based on usage data from memory cards, or for o60% of the night and for o5 nights per week
based on the questionnaire. Non-users did not use positive airway pressure and had no other specific OSA
therapy, including surgery or a mandibular advancement device. The sample included 240 (51%) adherent
patients and 156 (33%) non-users. 71 (15%) partial-users (patients using positive airway pressure, but not
meeting ‘‘adherent’’ criteria) were excluded from treatment effect analyses.
Statistical analysis
Baseline associations
Continuous and categorical covariates are presented as mean¡SD and percentages, respectively, and
compared among groups with T-tests or ANOVA and Chi-squared or Fisher’s exact tests. Baseline lipid
levels were natural log transformed for normality; associations with obesity and OSA severity were assessed
using Pearson correlations.
Propensity score methodologies
We used sub-classification by propensity score quintiles to select samples of adherent patients and non-
users in which to assess the positive airway pressure treatment effect, based on an established heuristic
described by MAISLIN and RUBIN [24]. Briefly, the heuristic consists of three stages that can be repeated as
necessary in order to satisfy a set of ‘‘propensity score diagnostics’’ [24]. First, a main effects propensity
score model including all desired covariates is fitted to obtain propensity score quintiles. Secondly, within-
quintile bias effect sizes and other propensity score diagnostic information are analysed to identify the
most important cross-product and squared terms for inclusion in the propensity score model. Thirdly,
a propensity score model including all main effects and relevant cross-product and squared terms is
estimated, and subjects in each treatment group with insufficient ‘‘covariate overlap’’ (as defined by the
propensity scores) are excluded from the sample.
Of 240 adherent patients and 156 non-users in the observational sample, we identified 199 (83%) adherent
patients and 118 (76%) non-users balanced within propensity subclass for baseline age, sex, body mass
index (BMI), current smoking, presence of hypertension, cardiovascular disease and diabetes, exercise
participation, excessive alcohol use, Epworth Sleepiness Scale (ESS), OSA severity (AHI, oxygen
desaturation index, arterial oxygen saturation (SaO2) nadir, and percentage of time at SaO2 ,90) and
fasting lipid levels (total cholesterol, LDL-C, HDL-C and triglycerides). Balance with respect to the included
covariates was shown to be as good as that expected from randomisation, strengthening causal inferences.
Additional details and references about propensity score methodology are detailed in the online
supplementary material.
Treatment effect analyses
Using untransformed values, 2-year fasting lipid changes were calculated within subject. Treatment
differences were assessed using ANCOVA, controlling for propensity score subclass and baseline lipid levels.
Whether obesity moderated the association between positive airway pressure and lipid changes was tested
using a positive airway pressure by BMI group interaction effect. Given limited power for interaction tests,
treatment group comparisons were examined within BMI strata (,30, 30–35 and o35 kg?m-2) regardless
of interaction results. There was ,90% power to detect treatment differences explaining 2.5% of variability
(R2) in lipid changes (online supplementary material).
Results
Baseline study population
A comparison of the 193 (24%) users of lipid-lowering medication and 613 (76%) non-users is presented in
table E1. Users were older (p,0.0001), had higher AHI (p50.039) and percentage of time at SaO2 ,90%
(p50.023), and greater prevalence of hypertension (p,0.0001), diabetes (p,0.0001) and cardiovascular
disease (p,0.0001) compared to lipid-lowering medication non-users. Medication users had similar BMI,
HDL-C and triglyceride levels as non-users, but lower total cholesterol (p,0.0001) and LDL-C (p,0.0001).
Table 1 shows baseline characteristics for lipid-lowering medication non-users stratified by BMI. Obese
patients were younger, participated less in exercise, and had more prevalent hypertension and diabetes and
more severe OSA. Compared to subjects with a BMI ,30 kg?m-2, patients with a BMI o35 kg?m-2 had
lower total cholesterol, LDL-C and HDL-C, but higher triglyceride levels (all p,0.02).
MRI was available in 501 (82%) subjects. The reasons for missing MRI included claustrophobia (n566),
poor quality images (n533), very high obesity (n56) and nonspecific reasons (n57). Table E2 compares
patients with and without MRI.
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Baseline associations with fasting lipids
Associations with baseline fasting lipids for obesity measures and OSA severity in lipid-lowering medication
non-users are shown in tables 2 and E3. BMI, weight, neck circumference and waist circumference were
negatively correlated with total cholesterol, LDL-C and HDL-C, and positively correlated with triglycerides.
Waist-to-hip ratio correlated with HDL-C and triglycerides only. All MRI fat measures were positively
correlated with triglycerides; visceral fat was negatively correlated with HDL-C. AHI was positively
correlated with HDL-C. No other correlations between OSA severity and lipid levels were observed.
Propensity score designed observational study
Sub-classification using propensity score quintiles identified 199 (83%) adherent patients and 118 (76%)
non-users meeting model assumptions assuring that, within subclass, distributions of included baseline
covariates were the same for both groups. Table E4 compares patients who were included and excluded
from the propensity score designed comparison.
Demographics and covariate balance
Figure 1, a modified version of a Love plot [29], and table 3 show that our propensity score designed study
resulted in baseline covariate balance between adherent patients and non-users (see Methods). In the
original observational cohort, eight out of 18 covariates were significantly different between adherent
patients and non-users (fig. 1). After adjusting for propensity score subclass in the designed study, no
baseline covariate differences remained (table 3).
Table 3 also summarises 2-year follow-up characteristics of the selected patients. We observed signi-
ficant differences between groups in BMI, ESS and smoking status. Both positive airway pressure groups
had lower ESS scores at follow-up, but adherent patients had greater decreases than non-users (p50.002).
Adherent patients also had increased BMI at follow-up compared to non-users (p,0.0001). Non-users
were more likely to become smokers (p50.004); 86% of patients who became smokers had a previous
smoking history.
TABLE 1 Baseline characteristics of the study population stratified by body mass index (BMI) group
Characteristic BMI ,30 kg?m-2 BMI 30–35 kg?m-2 BMI o35 kg?m-2 p-value#
Subjects n 186 210 217
Age years 54.4¡9.6 53.8¡10.8 50.5¡10.8 ,0.001
Male 82.3 81.0 78.3 0.597
BMI kg?m-2 27.4¡2.0 32.4¡1.4 39.9¡4.1 ,0.0001
Current smoker 24.3 20.5 22.7 0.654
Excessive alcohol 3.3 3.8 3.7 0.963
Hypertension 25.4 34.0 50.9 ,0.0001
Cardiovascular disease 3.2 4.8 4.6 0.769
Diabetes mellitus 2.2 2.4 6.5 0.045
Participate in exercise 73.6 57.6 51.9 ,0.0001
Epworth Sleepiness Scale 11.7¡4.8 11.4¡5.1 12.3¡5.3 0.183
AHI events?h-1 37.4¡15.2 44.7¡20.4 49.0¡23.2 ,0.0001
ODI events?h-1 26.4¡13.4 35.1¡18.9 41.9¡23.5 ,0.0001
SaO2 nadir 79.0¡6.6 76.9¡7.5 73.2¡8.9 ,0.0001
Percentage of time SaO2 ,90% 6.1¡9.1 12.4¡16.1 19.7¡22.3 ,0.0001
Total cholesterol mg?dL-1 212.6¡37.3 207.2¡42.4 200.9¡41.5 0.016
Total cholesterol o200" 65.6 57.6 52.5 0.029
LDL cholesterol mg?dL-1 156.1¡35.2 152.1¡38.2 145.4¡36.9 0.012
LDL cholesterol o130" 76.3 71.9 65.0 0.040
HDL cholesterol mg?dL-1 43.6¡14.3 39.6¡9.2 38.2¡9.4 ,0.0001
HDL cholesterol ,40" 48.4 57.1 67.3 0.001
Triglycerides mg?dL-1 147.1¡63.2 177.9¡81.6 198.9¡103.2 ,0.0001
Triglycerides o150" 43.0 59.5 68.7 ,0.0001
Data are presented as mean¡ SD or %, unless otherwise stated. All differences were significant except for the following characteristics:
sex, current smoker, excessive alcohol use, Epworth Sleepiness Scale score and cardiovascular disease. AHI: apnoea/hypopnoea index;
ODI: oxygen desaturation index; SaO2: arterial oxygen saturation; LDL: low-density lipoprotein; HDL: high-density lipoprotein.
#: from ANOVA
and Chi-squared or Fisher’s exact test; ": based on the National Cholesterol Education Programme (Adult Treatment Panel III) published
criteria [28].
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Differences in fasting lipid changes between positive airway pressure adherent patients and non-users
Summary measures of fasting lipid levels are presented in table 3. Since baseline lipid levels were included in
the propensity score heuristic, there were no differences in fasting lipids between adherent patients and non-
users at baseline.
Table 4 and figure 2 show 2-year fasting lipid changes between adherent patients and non-users, adjusted
for propensity score subclass and baseline lipid level. We observed no significant differences in lipid changes
between positive airway pressure groups, overall or within BMI strata. There was no evidence for interaction
between positive airway pressure and BMI group.
We examined differences in changes in the proportion of patients with abnormal lipid levels (table E5);
there were no differences between positive airway pressure adherent patients and non-users in the overall
sample. Within subjects with a BMI ,30 kg?m-2, the decrease in proportion of patients with abnormal
HDL-C was greater in adherent patients compared to non-users (p50.024) (table E5). The reason for this
result is unclear, given that there were no differences between positive airway pressure groups for mean
HDL change (p50.750) (table 4) or the proportion of patients near the abnormal HDL-C cut-off point
TABLE 2 Pearson correlations# between obesity and obstructive sleep apnoea severity measures and natural log transformed
lipid measures
Total cholesterol LDL cholesterol HDL cholesterol Triglycerides
rho p-value rho p-value rho p-value rho p-value
BMI kg?m-2 -0.13 0.001 -0.14 0.001 -0.16 ,0.001 0.28 ,0.0001
Weight kg -0.16 ,0.0001 -0.17 ,0.0001 -0.16 ,0.001 0.25 ,0.0001
Neck circumference cm -0.13 0.002 -0.13 0.001 -0.20 ,0.0001 0.34 ,0.0001
Waist circumference cm -0.11 0.006 -0.13 0.001 -0.12 0.003 0.32 ,0.0001
Waist-to-hip ratio -0.04 0.290 -0.05 0.177 -0.10 0.013 0.29 ,0.0001
Total abdominal fat cm3 -0.02 0.657 -0.05 0.239 -0.07 0.118 0.29 ,0.0001
Subcutaneous abdominal fat cm3 -0.03 0.502 -0.07 0.140 -0.04 0.402 0.22 ,0.0001
Visceral abdominal fat cm3 0.00 0.937 -0.01 0.746 -0.11 0.016 0.33 ,0.0001
AHI events?h-1 0.04 0.300 0.01 0.725 0.09 0.022 0.03 0.428
ODI events?h-1 -0.01 0.901 -0.02 0.559 0.02 0.606 0.06 0.157
SaO2 nadir 0.02 0.568 0.02 0.621 0.04 0.384 -0.01 0.804
Percentage of time at SaO2 ,90%
" -0.02 0.571 -0.04 0.360 0.01 0.792 0.02 0.619
Significant correlations are shown in bold. LDL: low-density lipoprotein; HDL: high-density lipoprotein; BMI: body mass index; AHI: apnoea/
hypopnoea index; ODI: oxygen desaturation index; SaO2: arterial oxygen saturation.
#: correlations between obesity and lipids adjusted for age and
sex; correlations for obstructive sleep apnoea severity adjusted for age, sex and BMI; ": natural log transformed for normality.
Triglycerides
HDL cholesterol
LDL cholestrol
Total cholesterol
Time SaO2<90%
SaO2 nadir
ODI
AHI
ESS
BMI
Age
Alcohol use
Exercise
Diabetes
CVD
Hypertension
Current smoking
Male
T-statistic or signed square root of Chi-squared
-3-4 -2 -1 0 321 654
Original cohort
PS designed sample
FIGURE 1 A modified version of a Love Plot [29] illustrating the balance in covariates between positive airway pressure
adherent patients and non-users in the original cohort and after controlling for propensity score (PS) subclass within the
designed cohort. The plot shows the T-statistic or signed square root of the Chi-squared comparing covariates between
groups. While a number of covariates were significantly different prior to sub-classification, after controlling for PS
subclass in the designed cohort all statistics are close to zero. HDL: high-density lipoprotein; LDL: low-density
lipoprotein; SaO2: arterial oxygen saturation; ODI: oxygen desaturation index; AHI: apnoea/hypopnoea index; ESS:
Epworth Sleepiness Scale; BMI: body mass index; CVD: cardiovascular disease. ?????: absolute value of statistic ,0.5.
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(p.0.46) in patients with BMI ,30 kg?m-2. We found no differences between adherent patients and non-
users in the change in proportion of patients with abnormal HDL-C in other BMI strata. There were no
associations between the positive airway pressure group and the change in proportion of patients with
abnormal levels of other lipid measures.
Positive airway pressure effect within meaningful subgroups
Patients with abnormal baseline lipid levels
We examined the patients exhibiting abnormal lipid levels at baseline, where we would expect the greatest
positive airway pressure treatment effect. No group differences in fasting lipid changes were observed
(table E6). We found a significant interaction between positive airway pressure and BMI group for LDL-C
change (p50.041), probably driven by qualitative differences in the observed non-significant effects.
Patients with the most severe hypoxia
To compare results with recent data from animal models [9–11, 17–21], we limited our sample to patients
in the top quartile of percentage of time at SaO2 ,90%. No differences in fasting lipid changes between
positive airway pressure adherent patients and non-users were observed (table E7).
Discussion
In a large cohort of moderate-to-severe OSA patients, this study used sub-classification by propensity score
quintiles to minimise bias in the estimated differences between positive airway pressure adherent patients
and non-users. This observational study design involved using an algorithm that selected patients without
regard to outcome data so that within subclass, measured demographic and baseline variables achieved
balance that was at least as good as that expected through randomisation. Results do not support the
hypothesis that positive airway pressure significantly affects 2-year changes in fasting lipid levels. Thus,
TABLE 3 Baseline and follow-up characteristics of the positive airway pressure adherent patients and non-users within the
propensity score designed sample
Characteristic Baseline Follow-up
Adherent Non-user p-value# Adherent Non-user p-value"
Subjects n 199 118 199 118
Age years 51.8¡10.4 52.8¡10.0 0.996
Male 81.9 80.5 0.967
BMI kg?m-2 33.9¡5.9 33.1¡5.9 0.975 34.9¡6.1 32.9¡5.4 ,0.0001
Current smoker 20.6 20.3 0.897 18.7 28.0 0.004
Excessive alcohol 2.5 2.5 0.954 1.5 2.5 0.342
Hypertension 33.2 28.8 0.892 33.8 30.5 0.953
Cardiovascular disease 2.5 1.7 0.949 2.5 1.7 0.688
Diabetes mellitus 1.5 0.9 0.987 3.1 3.5 0.460
Participate in exercise 58.8 58.4 0.988 67.9 66.7 0.726
Epworth Sleepiness Scale 12.0¡5.0 11.5¡4.8 0.966 7.8¡4.6 9.3¡4.9 0.002
AHI events?h-1 44.8¡19.6 40.8¡19.8 0.931
ODI events?h-1 36.1¡19.3 32.1¡19.0 0.990
SaO2 nadir 76.2¡7.5 77.5¡7.3 0.993
Percentage of time at SaO2 ,90% 2.1¡1.0 1.8¡1.0 0.942
Total cholesterol mg?dL-1 204.7¡41.6 204.9¡35.4 0.917 211.4¡41.6 213.3¡36.0 0.528
Total cholesterol o200+ 56.3 55.1 0.727 64.3 63.6 0.771
LDL cholesterol mg?dL-1 149.4¡37.3 149.7¡33.8 0.933 149.5¡30.9 151.3¡33.3 0.475
LDL cholesterol o130+ 70.9 72.9 0.905 75.9 72.9 0.475
HDL cholesterol mg?dL-1 40.0¡12.4 39.8¡10.3 0.922 46.6¡12.8 47.3¡12.8 0.619
HDL cholesterol ,40+ 60.8 57.6 0.978 30.6 34.8 0.144
Triglycerides mg?dL-1 174.8¡86.1 176.0¡102.9 0.998 174.6¡88.9 167.9¡96.1 0.517
Triglycerides o150+ 59.8 55.1 0.737 54.8 49.2 0.544
Data are presented as mean¡SD or %, unless otherwise stated. Significant differences are shown in bold. BMI: body mass index; AHI: apnoea/
hypopnoea index; ODI: oxygen desaturation index; SaO2: arterial oxygen saturation; LDL: low-density lipoprotein; HDL: high-density lipoprotein.
#: adjusted for propensity score subclass from ANCOVA model or conditional logistic regression; ": from ANCOVA or conditional logistic examining
the difference in follow-up values, adjusted for propensity score subclass and baseline value; +: based on the National Cholesterol Education
Programme (Adult Treatment Panel III) published criteria [28].
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increased risk of cardiovascular events and atherosclerosis in OSA patients is unlikely to be related to
mechanisms involving the fasting lipid profile.
Despite evidence associating OSA with atherosclerotic cardiovascular disease [1], and the relationship
between dyslipidaemia and atherosclerosis [2], no definitive evidence points towards dyslipidaemia as the
mechanism linking OSA and atherosclerosis in humans [3–16]. We found no convincing association
between OSA severity and fasting lipids, only a weak positive correlation between AHI and HDL-C,
implying protection against atherosclerosis. Instead, we observed correlations between obesity and fasting
lipids. Multiple obesity measures were positively correlated with triglycerides and negatively correlated with
HDL-C, consistent with associations between obesity and ‘‘atherogenic dyslipidaemia’’, characterised by
elevated triglycerides and decreased HDL-C and associated with cardiovascular risk [30]. We found
significant, but weak, negative correlations between obesity and total cholesterol and LDL-C. Obesity is
associated with reduced lipoprotein lipase activity and increased production of very low density lipoprotein
[30]. Given the role of lipoprotein lipase in the conversion of very low density lipoprotein into LDL-C, this
reduced activity may explain these negative correlations with LDL, as well as the increased triglycerides [31].
To our knowledge, this study is the longest study to date exploring the relationship between positive airway
pressure and fasting lipids. This study focuses on the utility of propensity score methodologies in the
principled design of observational studies, which substantially strengthens causal inference. These methods
were used to select adherent patients and non-users with balance for measured covariates similar to that
expected through randomisation. Although balance is achieved for included variables, a limitation of the
propensity score methodologies is the inability to address unobserved variables, which are theoretically
controlled for in the context of a randomised controlled trial. While we recognise the potential for presently
unknown or unmeasured confounders to influence results, we included as many relevant variables as
possible. Including a large number of relevant covariates in the propensity score model reduces the
likelihood that unknown or unmeasured confounders significantly affect results, since variables not
included in the propensity score model are controlled for to the extent that they are correlated with those
that are included.
We found no differences in 2-year fasting lipid changes between positive airway pressure adherent patients
and non-users. There is no definitive clinical evidence supporting lipid changes with positive airway
pressure [8–16]. One randomised trial showing decreases in cholesterol was retracted [32]. PHILLIPS et al.
[15] explored the effect of 2 months of positive airway pressure on postprandial lipidaemia over 24 h,
TABLE 4 Differences in 2-year fasting lipid changes between positive airway pressure adherent
patients and non-users
Lipid BMI#," kg?m-2 Adherent Non-users p-value+
Total cholesterol Overall 6.5¡2.21 8.8¡2.81 0.528
,30 2.4¡4.0 9.7¡4.41 0.248
30–35 15.1¡3.41 10.9¡4.91 0.493
o35 1.8¡3.6 6.7¡5.3 0.468
LDL cholesterol Overall -0.2¡1.9 2.2¡2.5 0.475
,30 -5.7¡3.8 1.6¡4.1 0.210
30–35 6.4¡3.01 2.6¡4.3 0.481
o35 -1.4¡3.3 2.0¡4.8 0.579
HDL cholesterol Overall 6.7¡0.71 7.3¡0.91 0.619
,30 6.7¡1.21 7.3¡1.31 0.750
30–35 7.6¡1.01 8.2¡1.51 0.735
o35 5.6¡1.11 7.0¡1.61 0.501
Triglycerides Overall -0.9¡5.6 -7.1¡7.4 0.517
,30 17.5¡11.4 6.9¡12.5 0.548
30–35 8.9¡10.5 8.3¡14.9 0.976
o35 -26.4¡7.31 -29.1¡10.81 0.844
Data are presented as least square mean¡SE change, unless otherwise stated. BMI: body mass index; LDL:
low-density lipoprotein; HDL: high-density lipoprotein. #: the propensity score sample included 199 adherent
patients (BMI ,30: n556; BMI 30–35: n565; BMI o35: n578) and 118 non-users (BMI ,30: n547; BMI 30–35:
n533; BMI o35: n538); ": p50.557 for total cholesterol, p50.500 for LDL, p50.615 for HDL and p50.563 for
triglycerides; +: from ANCOVA comparing adherent patients and non-users within propensity score designed
study, adjusted for propensity score subclass and baseline lipid level; 1: within group estimate of lipid change
significantly (p,0.05) different from zero.
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observing decreased postprandial triglycerides and total cholesterol associated with positive airway pressure
use, and a small corresponding decrease in HDL. We did not study postprandial lipids; it is possible that
positive airway pressure use could have affected these. However, we note that PHILLIPS et al. [15] also
observed no significant effect of positive airway pressure usage on fasting lipid levels, supporting our
conclusions. KOHLER et al. [13] found that 2 weeks of positive airway pressure withdrawal was associated
with a significant decrease in triglycerides compared to continued therapeutic positive airway pressure, as
well as increased blood pressure and catecholamine levels. Thus, over the short-term, there was no
dyslipidaemia produced by OSA.
Rodent models more convincingly demonstrate dyslipidaemia proportional to duration and severity of
chronic intermittent hypoxia [9–11, 17–21]. LI et al. [19] found increased fasting serum lipids in lean
C57BL/6J mice exposed to 4 weeks of severe chronic intermittent hypoxia (inspiratory oxygen fraction 5%);
no change was observed with moderate chronic intermittent hypoxia (inspiratory oxygen fraction 10%)
[19]. In an attempt to replicate this in humans, we restricted our sample to the top quartile of hypoxia
severity, with little change in results (table E7). Recent publications [20, 21] suggest chronic intermittent
hypoxia induces dyslipidaemia and atherosclerosis by inhibiting clearance of triglyceride-rich lipoproteins.
In mice, chronic intermittent hypoxia increases angiopoietin-like 4 (Angptl4) expression in adipose tissue
via upregulation of hypoxia-inducible factor-1a [20, 21]. Increased Angptl4 inhibits activity of adipose
lipoprotein lipase, inhibiting triglyceride-rich lipoproteins clearance and resulting in increased cholesterol
and triglycerides [20, 21]. While nocturnal hypoxaemia severity (but not BMI or AHI) correlated with
Angptl4 mRNA levels in subcutaneous adipose tissue of obese bariatric surgery patients [21], more research
is needed to determine the relationship between Angptl4 and atherosclerosis in apneics. Conceivably,
differences exist in molecular pathways between humans and mice. A mechanism other than dyslipidaemia
is suggested by DRAGER et al. [14] who observed no difference in lipid changes in severe OSA patients
randomised to positive airway pressure versus no treatment, but decreases in carotid intima-media thickness
and carotid-femoral pulse-wave velocity, two early atherosclerosis markers.
24% of our patients used lipid-lowering medications. Given their known efficacy, analyses were performed
in patients not using these medications. Conceivably, the effect of OSA on fasting lipids might be most
apparent in patients on lipid-lowering medications, but the effect is masked by medication use. However,
we observed no differences in lipid changes between positive airway pressure adherent patients and non-
users with abnormal lipids not using lipid-lowering medications (table E6). Ultimately, in human
populations with widespread screening for lipid abnormalities and use of lipid-lowering medications,
whether OSA contributes to lipid levels may be unanswerable. Based on current results and previous
publications, we conclude that, given widespread use of lipid-lowering medications, changes in fasting lipid
levels are not the mechanism by which OSA contributes to cardiovascular risk.
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FIGURE 2 The 2-year fasting lipid changes are shown for positive airway pressure adherent patients and non-users,
adjusted for propensity score subclass and baseline lipid level. There were statistically significant increases in total
cholesterol (TC; p50.003 in adherent patients and p50.002 in non-users) and high-density lipoprotein cholesterol
(HDL-C; p,0.0001 in both positive airway pressure groups) over 2 years, but there was no change in low-density
lipoprotein cholesterol (LDL-C) or triglycerides (TG). There were no differences in 2-year fasting lipid changes between
adherent patients and non-users. Data are presented as mean with 95% CI.
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Despite there being no relationship between positive airway pressure and fasting lipid changes, we observed
effects on BMI and subjective sleepiness changes, as in previous publications [33, 34]. Adherent patients had
an average increase in BMI of 1 kg?m-2 over follow-up, compared to no change in non-users, confirming a
recent report from the Apnea Positive Pressure Long-term Efficacy Study (APPLES) study [33]. While the
mechanism causing increased BMI in positive airway pressure adherent patients is unclear, previous studies
have suggested increased energy expenditure associated with OSA, and that positive airway pressure
treatment reduces this expenditure [33, 35, 36]. Decreased energy expenditure among adherent patients, in
the absence of increased exercise or dietary changes, could result in weight gain. Both positive airway
pressure groups reported less subjective sleepiness at follow-up, but positive airway pressure adherent
subjects had a significantly larger mean ESS decrease than non-users (4.0 versus 2.5 points). Previous
research with sham-continuous positive airway pressure showed reductions in subjective sleepiness
attributed to a placebo effect [34]. While the reduction in sleepiness in our non-users is unexplained, it
cannot be produced by a placebo effect.
Our study has strengths, but some limitations. The Icelandic population is a population of European
descent and clinical practice in Iceland is identical to that in other countries. Results are expected to be
generalisable to moderate-to-severe OSA patients of similar ethnicity. However, additional studies involving
populations that include other ethnicities would be useful for increasing generalisability. The sample reflects
the Icelandic population diagnosed with OSA, but consequently contains a relative lack of females. Our
sample contained patients with moderate-to-severe OSA and no control population, potentially
limiting the ability to observe correlations between OSA severity and fasting lipids. However, positive
airway pressure non-users provided a ‘‘control’’ sample for analyses of OSA treatment response. While
patients were treated with positive airway pressure over 2 years, the design of the cohort was such that
adherence information was obtained over the period closest to follow-up. The reason for this was two-fold:
1) adherence information most proximal to the follow-up reassessments was believed to be the most
relevant; and 2) levels of compliance near the 2-year follow-up are probably representative of overall
adherence, as several publications have shown a significant relationship between early and long-term
positive airway pressure compliance [37–40]. Detailed phenotyping allowed for assessment of various
confounders, however, we cannot exclude the potential for unmeasured or unknown covariates to
influence results.
We have shown how sub-classification by propensity scores strengthens the causal inferences permitted by
the data. The approach allows simultaneous control for a greater number of covariates than multivariable
regression. Compared to regression adjustment, propensity methods are applied at the design stage without
access to outcome data, thereby reducing bias. Our approach was more inclusive of all real-world patients, a
benefit compared to typical randomised trials, while addressing the challenge of selection bias by essentially
reconstructing a stratified randomised design. Propensity score methodologies should be considered
whenever nonrandomised group comparisons are required, as advocated by the National Heart, Lung and
Blood Institute [23].
In conclusion, our study does not support a role for OSA in determining the fasting lipid profile. While
dyslipidaemia is a well-recognised atherosclerosis risk factor, our results suggest that changes in fasting lipids
are not the mechanism for the increased atherosclerotic cardiovascular morbidity and mortality seen in OSA.
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